Drug intelligence / Profile preview

NGM395

Development stage: Phase 1
Lead developer: NGM Biopharmaceuticals
Modality: Cytokines & Interferons → Recombinant Proteins and Enzymes
Administration: Subcutaneous

Overview

NGM395 is an engineered long-acting analogue of growth differentiation factor 15 (GDF15), a human hormone. It acts as an agonist of the glial cell line-derived neurotrophic factor receptor (GDNFR/GFRAL) and is being developed for metabolic diseases, specifically obesity and non-alcoholic fatty liver disease (NAFLD). The drug was originally developed by NGM Biopharmaceuticals. Its mechanism involves mimicking or replacing GDF15 to activate its receptor pathway, which plays a role in regulating appetite and energy balance. Clinical development reached phase 1 trials for both obesity and NAFLD[1][2][3][6].

Targets

GFRAL (Glial-derived neurotrophic factor family receptor alpha-like/ret receptor complex)

Beyond the preview

Go deeper on NGM395.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NGM395.

Explore the full profile